Allogeneic Gammadelta T Cells Combined With Interferon-α1b or PD-1 Monoclonal Antibody in Stage III-IV Amenable to Surgical Resection Melanoma - Trial NCT06212388
Access comprehensive clinical trial information for NCT06212388 through Pure Global AI's free database. This Phase 1 trial is sponsored by Xijing Hospital and is currently Not yet recruiting. The study focuses on Melanoma. Target enrollment is 10 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Xijing Hospital
Timeline & Enrollment
Phase 1
Jan 24, 2024
Oct 30, 2028
Primary Outcome
Rate of Pathological Complete Response (pCR),Rate of Major Pathological Response (mPR),Rate of Partial Pathological Response (pPR),Overall Response Rate(ORR)
Summary
The purpose of this study is to evaluate the efficacy and safety of allogeneic γδ T cells
 combined with recombinant human interferon-α1b (IFN-α1b) or PD-1 monoclonal antibody in
 neoadjuvant treatment of patients with Stage III-IV resectable melanoma.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06212388
Non-Device Trial